Literature DB >> 24462819

Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China.

Jiang Long1, Guo-pei Luo1, Zhi-wen Xiao1, Zu-qiang Liu1, Meng Guo1, Liang Liu1, Chen Liu1, Jin Xu1, Yu-tang Gao2, Ying Zheng3, Chunxiao Wu3, Quan-xing Ni1, Min Li4, Xianjun Yu5.   

Abstract

A multi-center population-based study in Shanghai, China was performed to explore the implications for the management of pancreatic cancer by comparing diagnosis and survival rates. Novel imaging modalities including MRI (13.9%), PET/CT (1.8%), and EUS (5.6%) were not widely used in our population. Only 39.7% of cases were histologically verified (surgery with histologic diagnosis 31.0%, cytological diagnosis 8.7%, surgery without histologic diagnosis 12.1%, and clinical diagnosis 48.2%). Overall, 30.0% of patients underwent curative-intent operation, and only 9.8% of patients received comprehensive treatment. The prognosis of pancreatic cancer patients was significantly better for patients who were treated in high-volume centers than in low-volume centers. We propose that more effort should be put on novel diagnostic modalities, histological confirmation, and comprehensive treatment in China. Multidisciplinary teams specialized in pancreatic cancer therapy in high-volume centers are urgently needed.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Pancreatic cancer; Prognosis; Shanghai; Survival

Mesh:

Year:  2014        PMID: 24462819     DOI: 10.1016/j.canlet.2014.01.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  49 in total

1.  On pancreatic cancer screening by magnetic resonance imaging with the recent evidence by Del Chiaro and colleagues.

Authors:  Yì-Xiáng J Wáng; Jing-Shan Gong; Romaric Loffroy
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

2.  Reverse correlation of Jab1 and Smad4 in PANC-1 cells involved in the pathogenesis of pancreatic cancer.

Authors:  Jun Li; Zhuoyu Gu; Siyuan Li; Zhiwei Xiao; Kan Sun
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

3.  The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).

Authors:  Tao Lianyuan; Xiu Dianrong; Yuan Chunhui; Ma Zhaolai; Jiang Bin
Journal:  Cancer Biol Ther       Date:  2018-02-22       Impact factor: 4.742

4.  Polymorphisms in UGT2B4 and susceptibility to pancreatic cancer.

Authors:  Xu Che; Dianke Yu; Zongyong Wu; Jianwei Zhang; Yintai Chen; Yaling Han; Chenfeng Wang; Jun Qi
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 5.  Current status and progress of pancreatic cancer in China.

Authors:  Quan-Jun Lin; Feng Yang; Chen Jin; De-Liang Fu
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

6.  Anti-tumor effect and mechanism of cyclooxygenase-2 inhibitor through matrix metalloproteinase 14 pathway in PANC-1 cells.

Authors:  Siyuan Li; Zhuoyu Gu; Zhiwei Xiao; Ting Zhou; Jun Li; Kan Sun
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

7.  Babaodan Capsule () combined with Qingyi Huaji Formula () in advanced pancreatic cancer-a feasibility study.

Authors:  Li-Bin Song; Song Gao; Ai-Qin Zhang; Xiang Qian; Lu-Ming Liu
Journal:  Chin J Integr Med       Date:  2017-05-27       Impact factor: 1.978

8.  Overexpression of MYEOV predicting poor prognosis in patients with pancreatic ductal adenocarcinoma.

Authors:  Rui Tang; Jianmei Ji; Jun Ding; Jinxin Huang; Biao Gong; Xiwen Zhang; Fu Li
Journal:  Cell Cycle       Date:  2020-05-18       Impact factor: 4.534

9.  Using circulating tumor cells to evaluate the efficacy of irreversible electroporation for unresectasble pancreatic cancer.

Authors:  Mao Lin; Mohammed Alnaggar; Shu-Zhen Liang; Jian Shi; Li-Zhi Niu; Ji-Bing Chen; Ke-Cheng Xu
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

10.  UCHL3 promotes aerobic glycolysis of pancreatic cancer through upregulating LDHA expression.

Authors:  Y Fan; D Hu; D Li; C Ma; Y Tang; Q Tao; L Deng; D Tang
Journal:  Clin Transl Oncol       Date:  2021-02-22       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.